Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.

Details

Serval ID
serval:BIB_86BBC6AFEB18
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Journal
European journal of nuclear medicine and molecular imaging
Author(s)
Seban R.D., Moya-Plana A., Antonios L., Yeh R., Marabelle A., Deutsch E., Schwartz L.H., Gómez RGH, Saenger Y., Robert C., Ammari S., Dercle L.
ISSN
1619-7089 (Electronic)
ISSN-L
1619-7070
Publication state
Published
Issued date
09/2020
Peer-reviewed
Oui
Volume
47
Number
10
Pages
2301-2312
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
To compare the prognostic value of imaging biomarkers derived from a quantitative analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or cutaneous melanoma (Cut-M) treated with immune checkpoint inhibitors (ICIs).
In this retrospective monocentric study, we included 56 patients with non-resectable Muc-M (n = 24) or Cut-M (n = 32) who underwent baseline 18F-FDG-PET/CT before treatment with ICIs between 2011 and 2017. Parameters were extracted from (i) tumoral tissues: SUVmax, SUVmean, TMTV (total metabolic tumor volume), and TLG (total lesion glycolysis) and (ii) lymphoid tissues: BLR (bone marrow-to-liver SUVmax ratio) and SLR (spleen-to-liver SUVmax ratio). Association with survival and response was evaluated using Cox prediction models, Student's t tests, and Spearman's correlation respectively. p < 0.05 was considered significant.
Majority of ICIs were anti-PD1 (92.9%, n = 52/56). All 18F-FDG-PET/CT were positive. Overall (Muc-M to Cut-M), ORR was 33%:42%, DCR was 56%:69%, median follow-up was 25.0:28.9 months, median PFS was 4.7:10.7 months, and median OS was 23.9:28.3 months. In Muc-M, increased tumor SUVmax was associated with shorter OS while it was not correlated with PFS, ORR, or DCR. In Cut-M, increased TMTV and increased BLR were independently associated with shorter OS, shorter PFS, and lower response (ORR, DCR).
While all Muc-M and Cut-M were FDG avid, prognostic imaging biomarkers differed. For Muc-M patients treated with ICI, the only prognostic imaging biomarker was a high baseline maximal glycolytic activity (SUVmax), whereas for Cut-M patients, baseline metabolic tumor burden or bone marrow metabolism was negatively correlated to ICI response duration.
Keywords
CTLA-4 Antigen, Fluorodeoxyglucose F18, Humans, Immune Checkpoint Inhibitors, Melanoma/diagnostic imaging, Melanoma/drug therapy, Positron Emission Tomography Computed Tomography, Prognosis, Programmed Cell Death 1 Receptor, Retrospective Studies, Skin Neoplasms/diagnostic imaging, Skin Neoplasms/drug therapy, Tumor Burden, Biomarkers, Immunotherapy, Melanoma, Positron emission tomography computed tomography, Programmed cell death 1 receptor
Pubmed
Web of science
Create date
29/05/2021 14:38
Last modification date
19/11/2021 6:39
Usage data